SAINT LOUIS, MO – 24 Feb, 2016 – You can’t get to your destination, if you don’t know where you are going. The Cancer Moon Shot has taken on the goal of rapidly accelerating progress toward curing cancer. Primary thrusts of this initiative include optimizing big data and combining immunotherapies with more traditional cancer treatments. However, in order to treat cancer, it is necessary to find it. Even better is finding cancer early, when the odds of Moon Shot treatment success are greatest.
Cancer screening can contribute as much to curing cancer as the Cancer Moon Shot treatment initiative itself. Current screening methods for major cancers are less than perfect. Nonetheless, breast and lung cancer screening have been shown to improve cancer survival and find cancer early. Screening methods for most other cancers, including some deadly ones like pancreatic and ovarian cancer, do not exist. One reason for this is economic. It is not economically feasible to screen everyone for pancreatic or ovarian cancer when fewer than 25,000 cases of each occur annually.
To maximize the impact of the Cancer Moon Shot, cancer screening must be improved. Traxxsson, in collaboration with major research institutions, identified six blood biomarkers (proteins) that detect most cancers, including breast, colorectal, lung, ovarian, pancreatic, and kidney cancers. The Company’s CancSure™ test also provides probabilities as to which cancer is present. Screening for several cancers at once changes the economics of screening for rare cancers, since minimal cost is added to find them. Because the CancSure test can detect early, Stage I, cancers, the chances of curing your detected cancer with a Cancer Moon Shot treatment also are greatly improved.
Traxxsson’s CancSure test panel results are preliminary, and the tests are not yet commercially available. The Company’s first test to support breast cancer screening is expected to be available in late 2016. Traxxsson, LLC, located in Saint Louis, Missouri, has been developing cancer biomarkers since 2009 and has raised $1.5 million to date.
2009, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 151: 716-726.Wisnivesky, J. P., et. al., 2003, The Cost-Effectiveness of Low-Dose CT Screening for Lung Cancer, Chest, 124(2): 614-621. (http://www.ncbi.nlm.nih.gov/pubmed/12907551)
For additional information, contact: Info@traxxsson.com
(See also supplemental information: Table of improved outcomes based on lung cancer screening. For Dropbox link send email to: firstname.lastname@example.org)
Distributed by Press Release Jet
Company Name: Traxxsson, LLC
Contact Person: Robert Puskas
Country: United States